Chronic stable angina treatment lipid management: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Lakshmi Gopalakrishnan (talk | contribs)
nocaptcha
10,176 edits
No edit summary
Lakshmi Gopalakrishnan (talk | contribs)
nocaptcha
10,176 edits
No edit summary
Line 1: Line 1:
__NOTOC__
{{Chronic stable angina}}
{{Chronic stable angina}}
'''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; {{CZ}}; '''Associate Editors-In-Chief:''' [[John Fani Srour, M.D.]]; Jinhui Wu, MD


==ACC / AHA Guidelines for cardiovascular risk factor reduction- Lipid management (DO NOT EDIT) <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980 ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).] ''Circulation'' 99 (21):2829-48. [http://circ.ahajournals.org/content/99/21/2829.full.pdf] PMID: [http://pubmed.gov/10351980 10351980]</ref><ref name="pmid12515758">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12515758 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).] ''Circulation'' 107 (1):149-58.[http://content.onlinejacc.org/cgi/reprint/41/1/159.pdf] PMID: [http://pubmed.gov/12515758 12515758]</ref><ref name="pmid17998462">Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17998462 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina.] ''Circulation'' 116 (23):2762-72.[http://content.onlinejacc.org/cgi/reprint/50/23/2264.pdf] PMID: [http://pubmed.gov/17998462 17998462]</ref>==
'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; '''Associate Editor(s)-In-Chief:''' {{CZ}}; [[John Fani Srour, M.D.]]; [[WikiDoc Scholars#WikiDoc Scholars with Distinction|Jinhui Wu, M.D.]]; [[Lakshmi Gopalakrishnan|Lakshmi Gopalakrishnan. M.B.B.S.]]
{{cquote|
===Class I===
'''1.'''  Dietary therapy for all patients should include reduced intake of saturated fats (to less than 7% of total calories), transfatty acids, and cholesterol (to less than 200 mg per day). ''(Level of Evidence: B)''


'''2.''' Recommended lipid management includes assessment of a fasting lipid profile: ''(Level of Evidence: A)''
==Overview==
In patients with established [[coronary artery disease]], dietary interventions are effective to prevent future coronary events.<ref name="pmid12964575">De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12964575 European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.] ''Eur Heart J'' 24 (17):1601-10. PMID: [http://pubmed.gov/12964575 12964575]</ref> Based on the individual's lipid abnormalities, necessary dietary modifications may be suggested.<ref name="pmid1727199">Smith GD, Shipley MJ, Marmot MG, Rose G (1992) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1727199 Plasma cholesterol concentration and mortality. The Whitehall Study.] ''JAMA'' 267 (1):70-6. PMID: [http://pubmed.gov/1727199 1727199]</ref> A '''Mediterranean diet''' consisting of fruits, vegetables, lean meat and fish are recommended. '''Omega-3 fatty acid''' supplementation may be indicated in patients with [[Chronic stable angina definition|stable angina]] for secondary prevention, as it has shown to reduce elevated [[triglycerides]] and also reduce the risk of [[sudden cardiac arrest|sudden cardiac death]].<ref name="pmid10465168"> (1999) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10465168 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.] ''Lancet'' 354 (9177):447-55. PMID: [http://pubmed.gov/10465168 10465168]</ref><ref name="pmid11997274">Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R et al. (2002) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11997274 Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.] ''Circulation'' 105 (16):1897-903. PMID: [http://pubmed.gov/11997274 11997274]</ref><ref name="pmid11893369">Bucher HC, Hengstler P, Schindler C, Meier G (2002) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11893369 N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.] ''Am J Med'' 112 (4):298-304. PMID: [http://pubmed.gov/11893369 11893369]</ref><ref name="pmid15824290">Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC (2005) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15824290 Effect of different antilipidemic agents and diets on mortality: a systematic review.] ''Arch Intern Med'' 165 (7):725-30. [http://dx.doi.org/10.1001/archinte.165.7.725 DOI:10.1001/archinte.165.7.725] PMID: [http://pubmed.gov/15824290 15824290]</ref> '''Fish consumption''' once a week is associated with reduced risk of mortality from [[coronary artery disease]] and hence is strongly recommended.<ref name="pmid12588785">Kris-Etherton PM, Harris WS, Appel LJ, Nutrition Committee (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12588785 Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.] ''Arterioscler Thromb Vasc Biol'' 23 (2):e20-30. PMID: [http://pubmed.gov/12588785 12588785]</ref><ref name="pmid15184295">He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR et al. (2004) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15184295 Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies.] ''Circulation'' 109 (22):2705-11. [http://dx.doi.org/10.1161/01.CIR.0000132503.19410.6B DOI:10.1161/01.CIR.0000132503.19410.6B] PMID: [http://pubmed.gov/15184295 15184295]</ref>


:'''a.''' LDL-C should be less than 100 mg per dL. ''(Level of Evidence: A)''  
==ACC/AHA Guidelines- Pharmacotherapy to Prevent MI and Death and Reduce Symptoms (DO NOT EDIT) <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).]''Circulation'' 99 (21):2829-48. PMID: [http://pubmed.gov/10351980 10351980]</ref> <ref name="pmid12515758">Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12515758 ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).] ''Circulation'' 107 (1):149-58. PMID: [http://pubmed.gov/12515758 12515758]</ref> <ref name="pmid17998462">Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17998462 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina.] ''Circulation'' 116 (23):2762-72.[http://content.onlinejacc.org/cgi/reprint/50/23/2264.pdf] PMID: [http://pubmed.gov/17998462 17998462]</ref>==
 
{{cquote|
:'''b.''' If baseline [[LDL]]-C is greater than or equal to 100 mg per dL, LDL-lowering drug therapy should be initiated in addition to therapeutic lifestyle changes. When LDL lowering medications are used in high-risk or moderately high-risk persons, it is recommended that intensity of therapy be sufficient to achieve a 30% to 40% reduction in [[LDL]]-C levels.. ''(Level of Evidence: A)''
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]===
'''1.''' Dietary therapy for all patients should include reduced intake of saturated fats (to less than 7% of total calories), transfatty acids, and cholesterol (to less than 200 mg per day). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''


:'''c.''' If on-treatment [[LDL]]-C is greater than or equal to 100 mg per dL, LDL-lowering drug therapy should be intensified. ''(Level of Evidence: A)''
'''2.''' Daily [[Chronic stable angina treatment physical activity|physical activity]] and [[Chronic stable angina treatment weight management|weight management]] are recommended for all patients. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''


:'''d.''' If [[triglycerides]] are 200 to 499 mg per dL, non–[[HDL]]-C‡ should be less than 130 mg per dL. ''(Level of Evidence: B)''
'''3.''' Recommended lipid management includes assessment of a [[Coronary risk profile (patient information)|fasting lipid profile]].
:'''a.''' [[LDL|LDL-C]] should be less than 100 mg per dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''
:'''b.''' If baseline [[LDL|LDL-C]] is greater than or equal to 100 mg per dL, LDL-lowering drug therapy should be initiated in addition to therapeutic lifestyle changes. When LDL-lowering medications are used in high-risk or moderately high-risk persons, it is recommended that intensity of therapy be sufficient to achieve a 30% to 40% reduction in [[LDL|LDL-C]] levels. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''
:'''c.''' If on-treatment [[LDL|LDL-C]] is greater than or equal to 100 mg per dL, LDL-lowering drug therapy should be intensified. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''
:'''d.''' If [[triglycerides|TG]] are 200 to 499 mg per dL, [[HDL|non–HDL-C]] should be less than 130 mg per dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
:'''e.''' If [[triglycerides|TG]] are greater than or equal to 500 mg per dL, therapeutic options to lower the [[triglycerides|TG]] to reduce the risk of [[pancreatitis]] are fibrate or niacin; these should be initiated before [[LDL|LDL-C]] lowering therapy. The goal is to achieve [[HDL|non–HDL-C]] less than 130 mg per dL if possible. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''


:'''e.''' If [[triglycerides]] are greater than or equal to 500 mg per dL, therapeutic options to lower the [[triglycerides]] to reduce the risk of [[pancreatitis]] are [[fibrate]] or [[niacin]]; these should be initiated before [[LDL]]-C lowering therapy. The goal is to achieve non–[[HDL]]-C‡ less than 130 mg per dL if possible. ''(Level of Evidence: C)''
'''4.''' Drug combinations are beneficial for patients on lipid
lowering therapy who are unable to achieve [[LDL|LDL-C]] less
than 100 mg per dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''


'''3.''' Drug combinations are beneficial for patients on lipid lowering therapy who are unable to achieve [[LDL]]-C less than 100 mg per dL. ''(Level of Evidence: C)''  
'''5.''' Lipid-lowering therapy in patients with documented [[CAD]] and [[LDL-LDL cholesterol]] greater than 130 mg/dL
with a target [[LDL]] of less than 100 mg/dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''


===Class IIa===
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===  
'''1.''' Dietary therapy with the addition of plant stanol/sterols (2 g per day) and/or viscous fiber (greater than 10 g per day) is reasonable to further lower [[LDL]]-C. ''(Level of Evidence: A)''
'''1.''' Adding plant stanol or sterols (2 g per day) and/or viscous fiber (greater than 10 g per day) is reasonable to further lower [[LDL|LDL-C]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''


'''2.''' Recommended lipid management includes assessment of a [[fasting lipid profile]]: ''(Level of Evidence: A)''
'''2.''' Lipid-lowering therapy in patients with documented [[CAD]] and [[LDL|LDL cholesterol]] 100 to 129 mg/dL, with a target LDL of 100 mg/dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''


:'''a.''' Reduction of [[LDL]]-C to less than 70 mg per dL or high-dose [[statin]] therapy is reasonable. ''(Level of Evidence: A)''
'''3.''' Recommended lipid management includes assessment of a [[Coronary risk profile (patient information)|fasting lipid profile]].
:'''a.''' Reduction of [[LDL|LDL-C]] to less than 70 mg per dL or high-dose statin therapy is reasonable. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''
:'''b.''' If baseline [[LDL|LDL-C]] is 70 to 100 mg per dL, it is reasonable to treat LDL-C to less than 70 mg per dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
:'''c.''' Further reduction of [[HDL|non–HDL-C]] to less than 100 mg per dL is reasonable, if [[triglycerides|TG]] are greater than or equal to 200 to 499 mg per dL. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''


:'''b.''' If baseline [[LDL]]-C is 70 to 100 mg per dL, it is reasonable to treat LDL-C to less than 70 mg per dL. ''(Level of Evidence: B)''
'''4.''' Therapeutic options to reduce [[HDL|non–HDL-C]] are:
:'''a.''' [[Niacin]] can be useful as a therapeutic option to reduce non–HDL-C (after [[LDL|LDL-C]]–lowering therapy) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
:'''b.''' [[Fibrate|Fibrate therapy]] as a therapeutic option can be useful to reduce non–HDL-C (after LDL-C–lowering therapy). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''


:'''c.''' Further reduction of non–[[HDL]]-C‡ to less than 100 mg per dL is reasonable, if [[triglycerides]] are greater than or equal to 200 to 499 mg per dL. ''(Level of Evidence: B)''
'''5.''' The following lipid management strategies can be beneficial:
:'''a.''' If [[LDL|LDL-C]] less than 70 mg per dL is the chosen target, consider drug titration to achieve this level to minimize side effects and cost. When LDL-C less than 70 mg per dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of greater than 50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''


:'''d.''' Therapeutic options to reduce non–[[HDL]]-C are: ''(Level of Evidence: B)''
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]===
 
'''1.''' For all patients, encouraging consumption of omega-3 fatty acids in the form of fish or in capsule form (1 g per day) for risk reduction may be reasonable. For treatment of elevated [[triglyceride|TG]], higher doses are usually necessary for risk reduction. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''}}
::'''i.''' Niacin can be useful as a therapeutic option to reduce non–[[HDL]]-C (after [[LDL]]-C–lowering therapy)§ or, ''(Level of Evidence: B)''
 
::'''ii.''' [[Fibrate]] therapy as a therapeutic option can be useful to reduce non–[[HDL]]-C‡ (after [[LDL]]-C–lowering therapy). ''(Level of Evidence: B)''
 
'''3.''' The following lipid management strategies can be beneficial: <ref name="pmid15249516">Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB et al. (2004) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15249516 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.] ''Circulation'' 110 (2):227-39. [http://dx.doi.org/10.1161/01.CIR.0000133317.49796.0E DOI:10.1161/01.CIR.0000133317.49796.0E] PMID: [http://pubmed.gov/15249516 15249516]</ref> ''(Level of Evidence: C)''
 
:'''a.''' If [[LDL]]-C less than 70 mg per dL is the chosen target, consider drug titration to achieve this level to minimize side effects and cost.
 
:'''b.''' When [[LDL]]-C less than 70 mg per dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of greater than 50% in LDL-C levels by either [[statins]] or LDL-C–lowering drug combinations.
 
===Class IIb===
'''1.''' For all patients, encouraging consumption of omega-3 fatty acids in the form of fish* or in capsule form (1 g per day) for risk reduction may be reasonable. For treatment of elevated [[triglycerides]], higher doses are usually necessary for risk reduction. ''(Level of Evidence: B)''}}


==Vote on and Suggest Revisions to the Current Guidelines==
==Vote on and Suggest Revisions to the Current Guidelines==
Line 52: Line 51:


==Sources==
==Sources==
*Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology <ref name="pmid16735367">{{cite journal| author=Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F et al.| title=Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. | journal=Eur Heart J | year= 2006 | volume= 27 | issue= 11 | pages= 1341-81 | pmid=16735367 | doi=10.1093/eurheartj/ehl001 | pmc= |url=url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735367 [http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-angina-FT.pdf]}} </ref>
*The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980 ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).] ''Circulation'' 99 (21):2829-48. [http://circ.ahajournals.org/content/99/21/2829.full.pdf] PMID: [http://pubmed.gov/10351980 10351980]</ref>
*The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid10351980">Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=10351980 ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).] ''Circulation'' 99 (21):2829-48. [http://circ.ahajournals.org/content/99/21/2829.full.pdf] PMID: [http://pubmed.gov/10351980 10351980]</ref>


Line 59: Line 56:


*The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid17998462">Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17998462 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina.] ''Circulation'' 116 (23):2762-72.[http://content.onlinejacc.org/cgi/reprint/50/23/2264.pdf] PMID: [http://pubmed.gov/17998462 17998462]</ref>
*The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina <ref name="pmid17998462">Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)[http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17998462 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina.] ''Circulation'' 116 (23):2762-72.[http://content.onlinejacc.org/cgi/reprint/50/23/2264.pdf] PMID: [http://pubmed.gov/17998462 17998462]</ref>
*Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology <ref name="pmid16735367">{{cite journal| author=Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F et al.| title=Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. | journal=Eur Heart J | year= 2006 | volume= 27 | issue= 11 | pages= 1341-81 | pmid=16735367 | doi=10.1093/eurheartj/ehl001 | pmc= |url=url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735367 [http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-angina-FT.pdf]}} </ref>


==References==
==References==

Revision as of 00:06, 6 September 2011

Chronic stable angina Microchapters

Acute Coronary Syndrome Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Classic
Chronic Stable Angina
Atypical
Walk through Angina
Mixed Angina
Nocturnal Angina
Postprandial Angina
Cardiac Syndrome X
Vasospastic Angina

Differentiating Chronic Stable Angina from Acute Coronary Syndromes

Pathophysiology

Epidemiology and Demographics

Risk Stratification

Pretest Probability of CAD in a Patient with Angina

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Test Selection Guideline for the Individual Basis

Laboratory Findings

Electrocardiogram

Exercise ECG

Chest X Ray

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Myocardial Perfusion Scintigraphy with Thallium

Echocardiography

Exercise Echocardiography

Computed coronary tomography angiography(CCTA)

Positron Emission Tomography

Ambulatory ST Segment Monitoring

Electron Beam Tomography

Cardiac Magnetic Resonance Imaging

Coronary Angiography

Treatment

Medical Therapy

Revascularization

PCI
CABG
Hybrid Coronary Revascularization

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina

Discharge Care

Patient Follow-Up
Rehabilitation

Secondary Prevention

Guidelines for Asymptomatic Patients

Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients

Landmark Trials

Case Studies

Case #1

Chronic stable angina treatment lipid management On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic stable angina treatment lipid management

CDC onChronic stable angina treatment lipid management

Chronic stable angina treatment lipid management in the news

Blogs on Chronic stable angina treatment lipid management

to Hospitals Treating Chronic stable angina treatment lipid management

Risk calculators and risk factors for Chronic stable angina treatment lipid management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3] Phone:617-632-7753; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [4]; John Fani Srour, M.D.; Jinhui Wu, M.D.; Lakshmi Gopalakrishnan. M.B.B.S.

Overview

In patients with established coronary artery disease, dietary interventions are effective to prevent future coronary events.[1] Based on the individual's lipid abnormalities, necessary dietary modifications may be suggested.[2] A Mediterranean diet consisting of fruits, vegetables, lean meat and fish are recommended. Omega-3 fatty acid supplementation may be indicated in patients with stable angina for secondary prevention, as it has shown to reduce elevated triglycerides and also reduce the risk of sudden cardiac death.[3][4][5][6] Fish consumption once a week is associated with reduced risk of mortality from coronary artery disease and hence is strongly recommended.[7][8]

ACC/AHA Guidelines- Pharmacotherapy to Prevent MI and Death and Reduce Symptoms (DO NOT EDIT) [9] [10] [11]

“

Class I

1. Dietary therapy for all patients should include reduced intake of saturated fats (to less than 7% of total calories), transfatty acids, and cholesterol (to less than 200 mg per day). (Level of Evidence: B)

2. Daily physical activity and weight management are recommended for all patients. (Level of Evidence: B)

3. Recommended lipid management includes assessment of a fasting lipid profile.

a. LDL-C should be less than 100 mg per dL. (Level of Evidence: A)
b. If baseline LDL-C is greater than or equal to 100 mg per dL, LDL-lowering drug therapy should be initiated in addition to therapeutic lifestyle changes. When LDL-lowering medications are used in high-risk or moderately high-risk persons, it is recommended that intensity of therapy be sufficient to achieve a 30% to 40% reduction in LDL-C levels. (Level of Evidence: A)
c. If on-treatment LDL-C is greater than or equal to 100 mg per dL, LDL-lowering drug therapy should be intensified. (Level of Evidence: A)
d. If TG are 200 to 499 mg per dL, non–HDL-C should be less than 130 mg per dL. (Level of Evidence: B)
e. If TG are greater than or equal to 500 mg per dL, therapeutic options to lower the TG to reduce the risk of pancreatitis are fibrate or niacin; these should be initiated before LDL-C lowering therapy. The goal is to achieve non–HDL-C less than 130 mg per dL if possible. (Level of Evidence: C)

4. Drug combinations are beneficial for patients on lipid lowering therapy who are unable to achieve LDL-C less than 100 mg per dL. (Level of Evidence: C)

5. Lipid-lowering therapy in patients with documented CAD and LDL-LDL cholesterol greater than 130 mg/dL with a target LDL of less than 100 mg/dL. (Level of Evidence: A)

Class IIa

1. Adding plant stanol or sterols (2 g per day) and/or viscous fiber (greater than 10 g per day) is reasonable to further lower LDL-C. (Level of Evidence: B)

2. Lipid-lowering therapy in patients with documented CAD and LDL cholesterol 100 to 129 mg/dL, with a target LDL of 100 mg/dL. (Level of Evidence: B)

3. Recommended lipid management includes assessment of a fasting lipid profile.

a. Reduction of LDL-C to less than 70 mg per dL or high-dose statin therapy is reasonable. (Level of Evidence: A)
b. If baseline LDL-C is 70 to 100 mg per dL, it is reasonable to treat LDL-C to less than 70 mg per dL. (Level of Evidence: B)
c. Further reduction of non–HDL-C to less than 100 mg per dL is reasonable, if TG are greater than or equal to 200 to 499 mg per dL. (Level of Evidence: B)

4. Therapeutic options to reduce non–HDL-C are:

a. Niacin can be useful as a therapeutic option to reduce non–HDL-C (after LDL-C–lowering therapy) (Level of Evidence: B)
b. Fibrate therapy as a therapeutic option can be useful to reduce non–HDL-C (after LDL-C–lowering therapy). (Level of Evidence: B)

5. The following lipid management strategies can be beneficial:

a. If LDL-C less than 70 mg per dL is the chosen target, consider drug titration to achieve this level to minimize side effects and cost. When LDL-C less than 70 mg per dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of greater than 50% in LDL-C levels by either statins or LDL-C–lowering drug combinations. (Level of Evidence: C)

Class IIb

1. For all patients, encouraging consumption of omega-3 fatty acids in the form of fish or in capsule form (1 g per day) for risk reduction may be reasonable. For treatment of elevated TG, higher doses are usually necessary for risk reduction. (Level of Evidence: B)

”

Vote on and Suggest Revisions to the Current Guidelines

Sources

  • The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina [9]
  • TheACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina [10]
  • The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina [11]
  • Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology [12]

References

  1. ↑ De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (17):1601-10. PMID: 12964575
  2. ↑ Smith GD, Shipley MJ, Marmot MG, Rose G (1992) Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 267 (1):70-6. PMID: 1727199
  3. ↑ (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354 (9177):447-55. PMID: 10465168
  4. ↑ Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105 (16):1897-903. PMID: 11997274
  5. ↑ Bucher HC, Hengstler P, Schindler C, Meier G (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112 (4):298-304. PMID: 11893369
  6. ↑ Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC (2005) Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165 (7):725-30. DOI:10.1001/archinte.165.7.725 PMID: 15824290
  7. ↑ Kris-Etherton PM, Harris WS, Appel LJ, Nutrition Committee (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23 (2):e20-30. PMID: 12588785
  8. ↑ He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR et al. (2004) Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 109 (22):2705-11. DOI:10.1161/01.CIR.0000132503.19410.6B PMID: 15184295
  9. ↑ 9.0 9.1 Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al. (1999)guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).Circulation 99 (21):2829-48. PMID: 10351980
  10. ↑ 10.0 10.1 Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107 (1):149-58. PMID: 12515758
  11. ↑ 11.0 11.1 Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J et al. (2007)2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116 (23):2762-72.[1] PMID: 17998462
  12. ↑ Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F; et al. (2006). [url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735367 [2] "Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology"] Check |url= value (help). Eur Heart J. 27 (11): 1341–81. doi:10.1093/eurheartj/ehl001. PMID 16735367.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_stable_angina_treatment_lipid_management&oldid=596616"